اشترك بالحزمة الذهبية واحصل على وصول غير محدود شمرا أكاديميا
تسجيل مستخدم جديدArtificial Intelligence in Dry Eye Disease
370
0
0.0
(
0
)
اسأل ChatGPT حول البحث
ﻻ يوجد ملخص باللغة العربية
Dry eye disease (DED) has a prevalence of between 5 and 50%, depending on the diagnostic criteria used and population under study. However, it remains one of the most underdiagnosed and undertreated conditions in ophthalmology. Many tests used in the diagnosis of DED rely on an experienced observer for image interpretation, which may be considered subjective and result in variation in diagnosis. Since artificial intelligence (AI) systems are capable of advanced problem solving, use of such techniques could lead to more objective diagnosis. Although the term `AI is commonly used, recent success in its applications to medicine is mainly due to advancements in the sub-field of machine learning, which has been used to automatically classify images and predict medical outcomes. Powerful machine learning techniques have been harnessed to understand nuances in patient data and medical images, aiming for consistent diagnosis and stratification of disease severity. This is the first literature review on the use of AI in DED. We provide a brief introduction to AI, report its current use in DED research and its potential for application in the clinic. Our review found that AI has been employed in a wide range of DED clinical tests and research applications, primarily for interpretation of interferometry, slit-lamp and meibography images. While initial results are promising, much work is still needed on model development, clinical testing and standardisation.
قيم البحث
اقرأ أيضاً
This study evaluated generative methods to potentially mitigate AI bias when diagnosing diabetic retinopathy (DR) resulting from training data imbalance, or domain generalization which occurs when deep learning systems (DLS) face concepts at test/inf
erence time they were not initially trained on. The public domain Kaggle-EyePACS dataset (88,692 fundi and 44,346 individuals, originally diverse for ethnicity) was modified by adding clinician-annotated labels and constructing an artificial scenario of data imbalance and domain generalization by disallowing training (but not testing) exemplars for images of retinas with DR warranting referral (DR-referable) and from darker-skin individuals, who presumably have greater concentration of melanin within uveal melanocytes, on average, contributing to retinal image pigmentation. A traditional/baseline diagnostic DLS was compared against new DLSs that would use training data augmented via generative models for debiasing. Accuracy (95% confidence intervals [CI]) of the baseline diagnostics DLS for fundus images of lighter-skin individuals was 73.0% (66.9%, 79.2%) vs. darker-skin of 60.5% (53.5%, 67.3%), demonstrating bias/disparity (delta=12.5%) (Welch t-test t=2.670, P=.008) in AI performance across protected subpopulations. Using novel generative methods for addressing missing subpopulation training data (DR-referable darker-skin) achieved instead accuracy, for lighter-skin, of 72.0% (65.8%, 78.2%), and for darker-skin, of 71.5% (65.2%,77.8%), demonstrating closer parity (delta=0.5%) in accuracy across subpopulations (Welch t-test t=0.111, P=.912). Findings illustrate how data imbalance and domain generalization can lead to disparity of accuracy across subpopulations, and show that novel generative methods of synthetic fundus images may play a role for debiasing AI.
Artificial intelligence (AI) has been transforming the practice of drug discovery in the past decade. Various AI techniques have been used in a wide range of applications, such as virtual screening and drug design. In this survey, we first give an ov
erview on drug discovery and discuss related applications, which can be reduced to two major tasks, i.e., molecular property prediction and molecule generation. We then discuss common data resources, molecule representations and benchmark platforms. Furthermore, to summarize the progress of AI in drug discovery, we present the relevant AI techniques including model architectures and learning paradigms in the papers surveyed. We expect that this survey will serve as a guide for researchers who are interested in working at the interface of artificial intelligence and drug discovery. We also provide a GitHub repository (https://github.com/dengjianyuan/Survey_AI_Drug_Discovery) with the collection of papers and codes, if applicable, as a learning resource, which is regularly updated.
Background: An increasing volume of prostate biopsies and a world-wide shortage of uro-pathologists puts a strain on pathology departments. Additionally, the high intra- and inter-observer variability in grading can result in over- and undertreatment
of prostate cancer. Artificial intelligence (AI) methods may alleviate these problems by assisting pathologists to reduce workload and harmonize grading. Methods: We digitized 6,682 needle biopsies from 976 participants in the population based STHLM3 diagnostic study to train deep neural networks for assessing prostate biopsies. The networks were evaluated by predicting the presence, extent, and Gleason grade of malignant tissue for an independent test set comprising 1,631 biopsies from 245 men. We additionally evaluated grading performance on 87 biopsies individually graded by 23 experienced urological pathologists from the International Society of Urological Pathology. We assessed discriminatory performance by receiver operating characteristics (ROC) and tumor extent predictions by correlating predicted millimeter cancer length against measurements by the reporting pathologist. We quantified the concordance between grades assigned by the AI and the expert urological pathologists using Cohens kappa. Results: The performance of the AI to detect and grade cancer in prostate needle biopsy samples was comparable to that of international experts in prostate pathology. The AI achieved an area under the ROC curve of 0.997 for distinguishing between benign and malignant biopsy cores, and 0.999 for distinguishing between men with or without prostate cancer. The correlation between millimeter cancer predicted by the AI and assigned by the reporting pathologist was 0.96. For assigning Gleason grades, the AI achieved an average pairwise kappa of 0.62. This was within the range of the corresponding values for the expert pathologists (0.60 to 0.73).
There is a growing interest in cactus cultivation because of numerous cacti uses from houseplants to food and medicinal applications. Various diseases impact the growth of cacti. To develop an automated model for the analysis of cactus disease and to
be able to quickly treat and prevent damage to the cactus. The Faster R-CNN and YOLO algorithm technique were used to analyze cactus diseases automatically distributed into six groups: 1) anthracnose, 2) canker, 3) lack of care, 4) aphid, 5) rusts and 6) normal group. Based on the experimental results the YOLOv5 algorithm was found to be more effective at detecting and identifying cactus disease than the Faster R-CNN algorithm. Data training and testing with YOLOv5S model resulted in a precision of 89.7% and an accuracy (recall) of 98.5%, which is effective enough for further use in a number of applications in cactus cultivation. Overall the YOLOv5 algorithm had a test time per image of only 26 milliseconds. Therefore, the YOLOv5 algorithm was found to suitable for mobile applications and this model could be further developed into a program for analyzing cactus disease.
The rise of Artificial Intelligence (AI) will bring with it an ever-increasing willingness to cede decision-making to machines. But rather than just giving machines the power to make decisions that affect us, we need ways to work cooperatively with A
I systems. There is a vital need for research in AI and Cooperation that seeks to understand the ways in which systems of AIs and systems of AIs with people can engender cooperative behavior. Trust in AI is also key: trust that is intrinsic and trust that can only be earned over time. Here we use the term AI in its broadest sense, as employed by the recent 20-Year Community Roadmap for AI Research (Gil and Selman, 2019), including but certainly not limited to, recent advances in deep learning. With success, cooperation between humans and AIs can build society just as human-human cooperation has. Whether coming from an intrinsic willingness to be helpful, or driven through self-interest, human societies have grown strong and the human species has found success through cooperation. We cooperate in the small -- as family units, with neighbors, with co-workers, with strangers -- and in the large as a global community that seeks cooperative outcomes around questions of commerce, climate change, and disarmament. Cooperation has evolved in nature also, in cells and among animals. While many cases involving cooperation between humans and AIs will be asymmetric, with the human ultimately in control, AI systems are growing so complex that, even today, it is impossible for the human to fully comprehend their reasoning, recommendations, and actions when functioning simply as passive observers.
الأسئلة المقترحة
سجل دخول لتتمكن من نشر تعليقات
التعليقات
جاري جلب التعليقات
سجل دخول لتتمكن من متابعة معايير البحث التي قمت باختيارها
